4D MOLECULAR THERAPEUTICS IN (FDMT) Stock Price, Quote, News and Overview
NASDAQ:FDMT - Nasdaq - US35104E1001 - Common Stock - Currency: USD
FDMT Quote, Performance and Key Statistics
3.57
-0.19 (-5.05%)
The current stock price of FDMT is 3.57 USD. In the past month the price increased by 28.88%. In the past year, price decreased by -86.11%.
FDMT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.09 | 346.84B | ||
| AMGN | AMGEN INC | 13.49 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1724.79 | 128.59B | ||
| GILD | GILEAD SCIENCES INC | 13.28 | 128.00B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.62 | 65.17B | ||
| ARGX | ARGENX SE - ADR | 345.61 | 40.09B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.58B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.40B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.30B | ||
| NTRA | NATERA INC | N/A | 21.40B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.81B | ||
| BIIB | BIOGEN INC | 7.7 | 17.85B |
Related stock screener links
About FDMT
Company Profile
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. The company is headquartered in Emeryville, California and currently employs 227 full-time employees. The company went IPO on 2020-12-11. The firm's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The firm is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The firm's non-core programs include 4D-175, 4D-725, and 4D-310.
Company Info
4D MOLECULAR THERAPEUTICS IN
5858 Horton Street #455, Emeryville
Emeryville CALIFORNIA US
Employees: 201
Phone: 15105052680
4D MOLECULAR THERAPEUTICS IN / FDMT FAQ
What is the stock price of 4D MOLECULAR THERAPEUTICS IN today?
The current stock price of FDMT is 3.57 USD. The price decreased by -5.05% in the last trading session.
What is the ticker symbol for 4D MOLECULAR THERAPEUTICS IN stock?
The exchange symbol of 4D MOLECULAR THERAPEUTICS IN is FDMT and it is listed on the Nasdaq exchange.
On which exchange is FDMT stock listed?
FDMT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for 4D MOLECULAR THERAPEUTICS IN stock?
17 analysts have analysed FDMT and the average price target is 30.37 USD. This implies a price increase of 750.8% is expected in the next year compared to the current price of 3.57. Check the 4D MOLECULAR THERAPEUTICS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is 4D MOLECULAR THERAPEUTICS IN worth?
4D MOLECULAR THERAPEUTICS IN (FDMT) has a market capitalization of 165.36M USD. This makes FDMT a Micro Cap stock.
How many employees does 4D MOLECULAR THERAPEUTICS IN have?
4D MOLECULAR THERAPEUTICS IN (FDMT) currently has 201 employees.
What are the support and resistance levels for 4D MOLECULAR THERAPEUTICS IN (FDMT) stock?
4D MOLECULAR THERAPEUTICS IN (FDMT) has a support level at 3.4 and a resistance level at 4. Check the full technical report for a detailed analysis of FDMT support and resistance levels.
Is 4D MOLECULAR THERAPEUTICS IN (FDMT) expected to grow?
The Revenue of 4D MOLECULAR THERAPEUTICS IN (FDMT) is expected to grow by 216.71% in the next year. Check the estimates tab for more information on the FDMT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy 4D MOLECULAR THERAPEUTICS IN (FDMT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of FDMT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of FDMT, evaluating the profitability, health, valuation and growth aspects
- 4D MOLECULAR THERAPEUTICS IN (FDMT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- 4D MOLECULAR THERAPEUTICS IN (FDMT) Sales and EPS estimates to see what analysts future expectations are.
- 4D MOLECULAR THERAPEUTICS IN (FDMT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- 4D MOLECULAR THERAPEUTICS IN (FDMT) Insider and Institutional Ownership to learn about the owners and their transactions.
- 4D MOLECULAR THERAPEUTICS IN (FDMT) Stock Chart to make your own analysis
- 4D MOLECULAR THERAPEUTICS IN (FDMT) Latest news and press-releases to stay up to date.
Does 4D MOLECULAR THERAPEUTICS IN (FDMT) stock pay dividends?
FDMT does not pay a dividend.
When does 4D MOLECULAR THERAPEUTICS IN (FDMT) report earnings?
4D MOLECULAR THERAPEUTICS IN (FDMT) will report earnings on 2025-05-08, after the market close.
What is the Price/Earnings (PE) ratio of 4D MOLECULAR THERAPEUTICS IN (FDMT)?
4D MOLECULAR THERAPEUTICS IN (FDMT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.98).
What is the Short Interest ratio of 4D MOLECULAR THERAPEUTICS IN (FDMT) stock?
The outstanding short interest for 4D MOLECULAR THERAPEUTICS IN (FDMT) is 11.69% of its float. Check the ownership tab for more information on the FDMT short interest.
FDMT Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to FDMT. When comparing the yearly performance of all stocks, FDMT is a bad performer in the overall market: 97.18% of all stocks are doing better.
FDMT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FDMT. FDMT has a great financial health rating, but its profitability evaluates not so good.
FDMT Financial Highlights
Over the last trailing twelve months FDMT reported a non-GAAP Earnings per Share(EPS) of -2.98. The EPS decreased by -12.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.71% | ||
| ROE | -31.51% | ||
| Debt/Equity | 0 |
FDMT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to FDMT. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of -22.19% and a revenue growth 216.71% for FDMT